DE60031260D1 - Vorübergehend-immortalisierte zellen zur verwendung in gentherapie - Google Patents

Vorübergehend-immortalisierte zellen zur verwendung in gentherapie

Info

Publication number
DE60031260D1
DE60031260D1 DE60031260T DE60031260T DE60031260D1 DE 60031260 D1 DE60031260 D1 DE 60031260D1 DE 60031260 T DE60031260 T DE 60031260T DE 60031260 T DE60031260 T DE 60031260T DE 60031260 D1 DE60031260 D1 DE 60031260D1
Authority
DE
Germany
Prior art keywords
polypeptide
cells
temporary
gene therapy
immortalized cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60031260T
Other languages
English (en)
Other versions
DE60031260T2 (de
Inventor
Edward Baetge
Shou Wong
Philippe Dupraz
Bernard Thorens
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Heart Biosystems GmbH
Original Assignee
Heart Biosystems GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/546,269 external-priority patent/US6730513B1/en
Application filed by Heart Biosystems GmbH filed Critical Heart Biosystems GmbH
Publication of DE60031260D1 publication Critical patent/DE60031260D1/de
Application granted granted Critical
Publication of DE60031260T2 publication Critical patent/DE60031260T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/60—Materials for use in artificial skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • C12N9/1276—RNA-directed DNA polymerase (2.7.7.49), i.e. reverse transcriptase or telomerase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/04—Immortalised cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE60031260T 1999-04-12 2000-04-12 Vorübergehend-immortalisierte zellen zur verwendung in gentherapie Expired - Lifetime DE60031260T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US546269 1990-06-29
US12889399P 1999-04-12 1999-04-12
US128893P 1999-04-12
US09/546,269 US6730513B1 (en) 1999-07-20 2000-04-10 Keratinocyte cultures and uses thereof
PCT/US2000/009775 WO2000061617A2 (en) 1999-04-12 2000-04-12 Transiently immortalized cells for use in gene therapy

Publications (2)

Publication Number Publication Date
DE60031260D1 true DE60031260D1 (de) 2006-11-23
DE60031260T2 DE60031260T2 (de) 2007-05-03

Family

ID=26827053

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60031260T Expired - Lifetime DE60031260T2 (de) 1999-04-12 2000-04-12 Vorübergehend-immortalisierte zellen zur verwendung in gentherapie

Country Status (8)

Country Link
EP (1) EP1175436B1 (de)
JP (1) JP2002541786A (de)
AT (1) ATE342275T1 (de)
AU (1) AU4342900A (de)
CA (1) CA2369884C (de)
DE (1) DE60031260T2 (de)
DK (1) DK1702979T3 (de)
WO (1) WO2000061617A2 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19933089A1 (de) * 1999-07-15 2001-01-18 Max Delbrueck Centrum Mittel zur Gewerbsregeneration
DE19933492B4 (de) * 1999-07-16 2008-01-10 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Konjugat zur Vermittlung eines zell-, kompartiment- oder membranspezifischen Transports von Wirksubstanzen, Verfahren zu dessen Herstellung und dessen Verwendung
WO2001049832A2 (en) * 2000-01-07 2001-07-12 Artemis Pharmaceuticals Gmbh Transduction of recombinases for inducible gene targeting
FR2810046B1 (fr) * 2000-06-07 2004-09-10 Neurotech Procede d'immortalisation conditionnelle de cellules et les constructions proteiques pour sa mise en oeuvre
AU2002226076A1 (en) * 2000-12-14 2002-06-24 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Telomerase immortalized human liver cell lines
US7521234B2 (en) 2001-03-16 2009-04-21 Naoya Kobayashi Mammalian immortalized liver cell
JP2002300900A (ja) * 2001-04-05 2002-10-15 National Institute Of Advanced Industrial & Technology 腫瘍悪性化因子および腫瘍悪性化を抑制する化合物のスクリーニング方法
GB0112818D0 (en) * 2001-05-25 2001-07-18 Lorantis Ltd Conjugate
DE50214367D1 (de) * 2001-10-18 2010-05-27 Heart Biosystems Gmbh Transiente immortalisierung von zellen durch onkogenproteine oder telomerproteine
US7166692B2 (en) 2003-03-04 2007-01-23 Canbrex Bio Science Walkersville, Inc. Intracellular delivery of small molecules, proteins, and nucleic acids
WO2006102716A1 (en) * 2005-04-01 2006-10-05 Medvet Science Pty. Ltd. A method of diagnosis and treatment and agents useful for same
CN101330830B (zh) * 2005-10-18 2016-01-20 国家犹太健康中心 条件无限增殖化长期干细胞和制备和使用所述细胞的方法
AU2014202016B2 (en) * 2005-10-18 2016-05-19 National Jewish Health Conditionally immortalized long-term stem cells and methods of making and using such cells
US8986702B2 (en) 2008-05-16 2015-03-24 Taiga Biotechnologies, Inc. Antibodies and processes for preparing the same
EP2318435B1 (de) 2008-08-28 2015-12-23 Taiga Biotechnologies, Inc. Myc-modulatoren, verfahren zu ihrer verwendung und verfahren zur identifikation von mitteln zur myc-modulierung
DE102010041958A1 (de) * 2010-10-04 2012-04-05 Medicyte Gmbh Geeignete Hepatozyten für in-vitro Genotoxitätstests
EP2877189B1 (de) 2012-07-20 2021-01-06 Taiga Biotechnologies, Inc. Verbesserte rekonstitution und autorekonstitution des hämatopoietischen kompartments
US10272115B2 (en) 2013-03-11 2019-04-30 Taiga Biotechnologies, Inc. Production and use of red blood cells
US9365825B2 (en) 2013-03-11 2016-06-14 Taiga Biotechnologies, Inc. Expansion of adult stem cells in vitro
EP2871233A1 (de) 2013-11-12 2015-05-13 Brandenburgische Technische Universität Cottbus-Senftenberg Verfahren zur Herstellung von biogenen Stoffen
CA3045017A1 (en) 2016-12-02 2018-06-07 Taiga Biotechnologies, Inc. Nanoparticle formulations
US10149898B2 (en) 2017-08-03 2018-12-11 Taiga Biotechnologies, Inc. Methods and compositions for the treatment of melanoma
CN114525238A (zh) * 2022-02-14 2022-05-24 中国农业科学院兰州兽医研究所 一株牛皮肤成纤维永生化细胞系的建立方法及应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE365808T1 (de) * 1995-07-28 2007-07-15 Marie Curie Cancer Care Transportproteine und deren verwendungen
US6495526B2 (en) * 1996-01-23 2002-12-17 Gpc Biotech, Inc. Inhibitors of cell-cycle progression and uses related thereto
US5770422A (en) * 1996-07-08 1998-06-23 The Regents Of The University Of California Human telomerase
US6017735A (en) * 1997-01-23 2000-01-25 Marie Curie Cancer Care Materials and methods for intracellular transport and their uses
DE19740571C1 (de) * 1997-09-15 1999-03-18 Gsf Forschungszentrum Umwelt Verfahren zur Stimulation von T-Zellen mit gewünschter Antigenspezifität
GB9720585D0 (en) * 1997-09-26 1997-11-26 Smithkline Beecham Biolog Vaccine
AU3665899A (en) * 1998-04-28 1999-11-16 Washington University Methods for transducing fusion molecules

Also Published As

Publication number Publication date
EP1175436A2 (de) 2002-01-30
JP2002541786A (ja) 2002-12-10
CA2369884C (en) 2010-01-05
WO2000061617A2 (en) 2000-10-19
DK1702979T3 (da) 2012-09-17
EP1175436B1 (de) 2006-10-11
CA2369884A1 (en) 2000-10-19
DE60031260T2 (de) 2007-05-03
AU4342900A (en) 2000-11-14
WO2000061617A3 (en) 2001-04-05
ATE342275T1 (de) 2006-11-15

Similar Documents

Publication Publication Date Title
DE60031260D1 (de) Vorübergehend-immortalisierte zellen zur verwendung in gentherapie
ATA165999A (de) Medium zur protein- und serumfreien kultivierung von zellen
AR018023A1 (es) Procedimiento para la fabricacion de polipeptidos con glicosilacion apropiada
ATE297987T1 (de) Bedingte immortalisierung von zellen
DK1650307T3 (da) Fremgangsmåde til fremstilling af rekombinante proteiner ved anvendelse af apoptoseinhibitorer
SE0201328D0 (sv) Hematopoietic differentiation of human embryonic stem cells
DK1266018T3 (da) Fremstilling af udskilte proteiner af rekombinante, eukaryotiske celler
DE60037450D1 (de) Funf-helix protein
ATE549395T1 (de) Medium und kultur von embryonalen stammzellen
MX9207397A (es) Recipientes para cultivo de celulas que tienen hileras interiores y metodo para cultivar celulas en los mismos.
AU2126688A (en) Serum free media for the growth of insect cells and expression of products thereby
BR0210599A (pt) Uso de monóxido de carbono, método para manutenção de uma célula animal in vitro, artigo de manufatura, bem como meio celular estéril
CO5580844A2 (es) Queratinocitos utilizables como sustancia biologicamente activa en el tratamiento de heridas
TR200200897T2 (tr) Melez matrisler ve melez matriks karışımları
MXPA05009096A (es) Metodo de cultivo celular libre de animal.
WO2005028626A3 (en) Cell culture media
EP1137808A4 (de) Methode zur herstellung von rekombinanten zellen
YU217890A (sh) Postupak za dobijanje genetskih konstrukcija za ekspresiju nervnog faktora rasta u eukariotskim ćelijama
ATE321843T1 (de) Zellen, kulturverfahren, und ihre verwendung in autologer transplantationstherapie
WO1999035245A3 (en) Methods for preparing and using immortalized human neuroendocrine cells
FR2716205B1 (fr) Récepteur galanine, acides nucléiques, cellules transformées et utilisations.
ATE517990T1 (de) Effektive kernumprogrammierung in säugetieren
AU2003222697A8 (en) Method for preparing tissue constructs
GB2379446A (en) Cells,culture methods and their uses
DE69920749D1 (de) Rekombinante bakterienstämme zur herstellung von natürlichen nucleosiden, sowie von modifizierten analogen davon

Legal Events

Date Code Title Description
8364 No opposition during term of opposition